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Nitric-oxide synthase, the enzyme responsible for mammalian nitric oxide generation,
and cytochrome P450, the major enzymes involved in drug metabolism, share
striking similarities. Therefore, it makes sense that cytochrome P450 drug mediated
biotransformations might play an important role in the pharmacological modulation
of nitric oxide synthase. In this work, we have undertaken an integrated in vitro
assessment of the hepatic metabolism and nitric oxide modulation of previously
described dual inhibitors (imidazoles and macrolides) of these enzymes in order assess
the implication of CYP450 activities over production of nitric oxide. In vitro systems
based in human liver microsomes and activated mouse macrophages were developed
for these purposes. Additionally in vitro production the hepatic metabolites of dual
inhibitor, roxithromycin, was investigated achieving the identification and isolation of
main hepatic biotransformation products. Our results suggested that for some macrolide
compounds, the cytochrome P450 3A4 derived drug metabolites have an important
effect on nitric oxide production and might critically contribute to the pharmacological
immunomodulatory activity observed.
Keywords: nitric, oxide CYP450, drug metabolism, immunomodulation
Abbreviations: AcN, Acetonitrile; AZT, Azithromycin; BFC, 7-Benzyloxy-4-(trifluoromethyl) coumarin; CID, Collision
induced dissociation; CLT, Clarithromycin; CYP3A4, Cytochrome P450 isoform 3A4; CYP450, cytochrome P450; DMSO,
Dimethyl sulfoxide; ERY, Erythromycin; HLM, Human liver microsomes; HPLC, High Performance liquid chromatography;
iNOS, Inducible nitric oxide synthase; IL, Interleukin; Kinact, Rate of enzyme inactivation for time dependent inhibitors;
KI, Inhibition constant for time dependent inhibitors; KS, Kinetic solubility; LC-HRMS, Liquid chromatography coupled
to high resolution mass spectrometry; LC-MS, Liquid chromatography coupled to mass spectrometry; LLE, Liquid-liquid
extraction; LPS, Lipopolysaccharide; MS, Mass spectrometry; MS/MS, Tandem mass spectrometry; N.A., Not Applicable;
NADPH, Reduced nicotinamide adenine dinucleotide phosphate; NIVA-CYPI-KS, Novel in vitro approach to simultaneously
assess CYP450 inhibition andKS solubility; NMR,Nuclearmagnetic resonance; NOS, Nitric-oxide synthase; NO,Nitric oxide;
QTOF, Quadrupole time of flight; RAW 264.7, Macrophage cell line; Abelson murine leukemia virus trans-formed; RXT,
Roxythromycin; STDVE, Standard deviation; SPE, Solid phase extraction; T1/2, Half-life; TDI, Time dependent inhibition;
TIC, Total ion chromatogram; UGT, Uridine diphosphate glucuronosyltransferase; XIC, Extracted ion chromatogram.
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INTRODUCTION
In a broad sense, nitric-oxide synthase (NOS) belongs to
the CY450 family since the label cytochrome P450 (CYP450)
has come to encompass a huge and widely distributed
group of closely related enzymes containing a thiolate-ligated
heme. Although structurally different, they have a mechanistic
resemblance since NOS converts L-arginine to L-citrulline
and nitric oxide (NO) through a P450-like process and
complementarily CYP450 was also found able to transform
N-hydroxy-L-arginine into NO and citrulline. Thus, the first
step in NO biosynthesis appears to have some precedence
in P450 chemistry (Gorren and Mayer, 2007). Perhaps most
striking among the similarities between CYP450 and NOS is
the fact that both the NOS oxygenase domain and mammalian
CYP450 utilize the same electron donor as a redox partner
(Masters, 2005). Given the extensive similarity between NOS
and CYP450 and the vast repertoire of drug P450-catalyzed
biotransformations (Bredt et al., 1991; Sono et al., 1996; Meunier
et al., 2004), it is worth assessing the role CYP450 might play
in the development of drug immunomodulation. Therefore, we
consider that molecules showing ability to inhibit NOS activity
might be especially prone to interact with CYP450 family. The
CYP450 is the main metabolic systems to deal with lipid-soluble
environmental chemicals and consequently it plays a critical role
in drug metabolism. The CYP450 system performs this function
by oxidizing, hydrolyzing or reducing the chemicals. This enables
another group of enzymes, conjugation enzymes, to attach polar
groups to make the metabolites water soluble so that they can be
excreted in the urine (Martin and Fay, 2001). Drug metabolism
might results in the production of both inactive and active
metabolites. In fact, activemetabolites might bemore potent than
the parent compound. Thus, although metabolism is ultimately a
process of detoxification, it produces intermediate products that
may have clinically useful activity, be associated with toxicity, or
both (Smith, 2009). Therefore the biological effectiveness and the
potential toxicity of NOS inhibitors might be strongly influenced
by their CYP450 metabolism.
Due to the association between the inappropriate release of
NO and the pathogenesis of a number of disease states, the
NOS isoforms (mainly the inducible isoform, iNOS) have become
attractive targets in drug design for various pathological states,
especially in neurodegenerative disorders, inflammation and pain
(Joubert and Malan, 2011).
Among known compounds able to prevent the biological
activity of NOS, we can find the antifungal imidazole derivate
family which is also recognized for strongly inhibiting the
enzymatic activity of several CYP450 isoforms (Niwa et al.,
2005). This inhibition of the NOS involves a putative binding
of the imidazole nitrogen to the heme iron, reducing the
maximal velocity of citrulline formation (Wolff et al., 1993).
Not surprisingly, in other mechanistic studies for evaluation of
CYP3A4 inhibition by imidazole derivatives, heme coordination
by the imidazole functional group was observed (Hutzler
et al., 2006). Analogously, macrolide antibiotics have long been
recognized to exert immunomodulatory and anti-inflammatory
actions, via inactivation of NO production (Gao et al., 2008;
Buret, 2010). In turn, some macrolide antibiotics have also been
found to form stable metabolic intermediate complexes with
the iron (II) present in the heme group of CYP450, after being
metabolized (Yamazaki and Shimada, 1998; Zweers-Zeilmaker
et al., 1999). Themain objective of this work was to assess in vitro,
the implication of the CYP450 activities in the modulation of
NO production. In this regard we proposed a working hypothesis
in which well-known compounds (imidazole derivatives &
macrolides) with the ability for inhibiting both activities (CYP450
and NOS) might display differential ability to inhibit NO
production depending on the CYP450 functionality of the cell
in vitro model considered. It has been extensively reported
that expression of biotranforming enzymes in immortalized
cell lines is much lower on average than that observed in
primary cells from liver, lung, blood, and skin (Soldatow et al.,
2013). Therefore if CYP450 activities are modulating to some
extent NO production by compound depletion or bioactive
metabolite formation, some differential effects in NO production
should be observed between in vitro models using cell lines or
primary cultures. To this end, we used an immunocompetent
in vitro model, but with limited CYP450 functionality, based
on lipopolysaccharide (LPS) stimulated, cultured cell lines of
murine macrophages (RAW 264.7) (Rodríguez-Antona et al.,
2002; Garrido-Mesa et al., 2010). These results were compared
with those retrieved from literature using primary cultures
of alveolar macrophages in which the pattern of CYP450
expression was found to closely resemble the expression pattern
in lung tissue (Hukkanen, 2000; Hukkanen et al., 2002). In
order to correlate NO measurements with CYP450 activity,
we also assessed the before mentioned dual inhibitors in
classical in vitro models for drug metabolism assessment such
as CYP450 reversible and time-dependent inhibition, aqueous
solubility and microsomal stability with metabolite identification
(Obach, 1999; Obach et al., 2006; Burt et al., 2010; Yang
et al., 2014; Perez et al., 2015). These in vitro studies using
microsomal fractions have historically provided critical and
basic information on drug metabolism by CYP450 which
is essential for prediction of the in vivo state (Cederbaum,
2015).
METHODS AND MATERIALS
Reagents
Fetal bovine serum (FBS), L-glutamine, sodium pyruvate, MEM
non-essential amino acids, penicillin–streptomycin, and TrypLE
Express were purchased from Invitrogen Gibco, Inc. (Life
Technologies, Carlsbad, CA). NP40 was purchased from Thermo
Scientific (Rockford, IL). Diphenyl tetrazolium bromide (MTT),
and methyl methane sulfonate (MMS) were obtained from Sigma
Aldrich. The commercial compounds evaluated in this work,
ketoconazole, miconazole, clotrimazole, erythromycin (ERY),
roxythromycin (RXT), azythromycin (AZT), and clarithromycin
(CLT), were obtained from Sigma Aldrich (St. Louis, MO).
Human recombinant c-DNA expressed CYP3A4 at 1 nmol/mL
was obtained from Gentest Corporation. Pooled human liver
microsomes (HLM) were obtained from Becton Dickinson
Gentest (Woburn, MA).
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Test Compound Preparation
For the simultaneous evaluation of CYP3A4 reversible
inhibition and solubility using the NIVA-CYPI-KS (Perez
et al., 2015), commercial compounds were prepared as follows:
test compounds were provided in powder form and dissolved
in 100% DMSO at 25 mM in 96-well plates. Serial dilutions of
test compounds in 100% DMSO were carried out on a Biomek
FX workstation coupled with a stacker carrousel (Beckman
Coulter Inc. Brea, California). Considering their previously
reported CYP3A4 inhibition potential, commercial compounds
were prepared at different initial concentrations and dilution
factors in order to optimize their IC50 calculation from a
titration curve with 8 concentration levels. Due to the extensively
reported ability of DMSO to inhibit CYP3A4 activity, diluted
compounds in 100% DMSO (35 µL) were combined with
AcN (65 µL) in 96-well microtiter plates (AB-0765, Thermo,
Waltham,MA) by a Perkin Elmer Evolution P3 liquid-dispensing
instrument (Waltham, Massachusetts) in order to minimize the
final DMSO content (0.35%) in enzyme incubations. DMSO
has been described as a potent inhibitor of several CYP450
isoforms (Chauret et al., 1998). Compounds for NO production
assessment were also prepared from serial dilutions in 100%
DMSO (20 µL) which were combined with water (80 µL). Initial
concentrations and dilution patterns were also adjusted for each
compound depending on the calculated solubility values and
expected response in NO production related studies (macrolides
and imidazole derivatives at ten concentration levels from 0.48
to 250 µM and from 0.019 to 10 µM, respectively).
Assays for NO Production Assessment in
LPS Stimulated Murine Macrophages
The mouse macrophage cells, RAW264.7 (ATCC R© TIB-71TM)
were obtained from ATCC and cultured in Dulbecco’s Modified
Eagle Medium (DMEM), supplemented with 10% FBS and 2 mM
l-glutamine, in a humidified 5% CO2 atmosphere at 37◦C. All cell
handling steps were carried out using the SelecT automated cell
culture system. RAW264.7 cells were seeded into 96-well plates at
a density of 20 × 103 cells per well and grown to approximately
50% of confluence (24 h). They were cultured for another 24
h with each of the test compounds described above (5 µL of
stock serial dilutions in 20% DMSO were dispensed into 190 µL
of fresh medium using Perkin Elmer Evolution P3, Waltham,
MA,). Afterwards, these cells were stimulated with LPS (5 µL
of 6 µg/mL were dispensed using a Thermo Scientific Multidrop
Combi dispenser, MTX Lab Systems, Vienna, VA). Untreated (5
µL of 20%DMSO, compound vehicle) and unstimulated (5µL of
purified water, LPS vehicle) cells were used as negative controls (n
= 4) while untreated but stimulated cells were used as positive
controls (n = 4) in each assay plate. After 24 h, supernatants
were collected and centrifuged at 10,000 × g for 5 min, and
nitrite levels were measured in 100 µL of supernatant according
to the Griess assay using a Thermo Scientific Multidrop
Combi dispenser and PerkinElmer EnVision Multilabel Reader
(Waltham, MA) (Green et al., 1982). After discarding the
remaining supernatant, the cell viability was examined in the
remaining cells through the MTT test described elsewhere and
also using a Thermo Scientific Multidrop Combi dispenser
and PerkinElmer EnVision Multilabel Reader (Mosmann, 1983).
Those compound concentrations showing cell viability < 80%
were rejected for further calculations.
Data Analysis
Test compound activities were calculated automatically using the
Genedata Screener software (Genedata AG, Basel, Switzerland),
and the percentage inhibition of each commercial compound was
determined by Equation (1), integrated in the Genedata Screener
software. Percentage of control of production of nitric oxide was:
Percentage of control =
(
Abswell − Absneg
Abspos − Absneg
)
∗ 100 (1)
where Abswell is the absorbance measured per specific well;
and Abspos and Absneg are the average absorbance measured
for the positive (LPS/solvent vehicle) and negative controls
(-LPS/solvent vehicle, respectively). IC50 values were calculated
as the compound concentration that inhibits the production
of NO by 50% using Genedata Screener software from dose-
response curves in the above described assays (0.5% DMSO
concentration). Dexamethasone was used as positive control
standard. All compounds were tested in triplicate (n = 3) in two
different days.
Statistical Tests
Data replicates are presented as mean values ± STDEV. The
coefficient of variation (relative STDEV) of each set of replicate
data was calculated. A set of replicate date was considered
acceptable if the coefficient of variation was ≤ 20 %.
Drug Metabolism Assessment
Simultaneous CYP3A4 Reversible Inhibition and
Turbidimetric Solubility Evaluation (NIVA-CYPI-KS)
In this work, we used a novel in vitro approach (NIVA-CYPI-
KS) to simultaneously assess CYP450 inhibition and aqueous
compound solubility as previously described (Perez et al.,
2015). Briefly, CYP3A4 inhibition studies were conducted
using human recombinant c-DNA expressed CYP3A4 enzymes
by quantification of non-fluorescent substrate, 7-benzyloxy-
4-(trifluoromethyl) coumarin (BFC) transformation to a
fluorescent product (7-HFC), which is mediated by CYP3A4. For
aqueous solubility assessment, serial dilutions of test compounds
(imidazole derivatives and macrolides) dissolved in DMSO/AcN
[35:65] [v/v] (2 µL) were combined with a 180 µL potassium
phosphate buffer (pH 7.4) using an Evolution P3 liquid handling
station. Then the plates were incubated for 2 h at 37◦C to
allow slow compound precipitation. Thereafter, absorbance was
measured at 620 nm by an EnVision multilabel plate reader.
Absorbance signals were used to determine compound solubility
limits. Pyrene was used as standard control for precipitation in
turbidimetric kinetic solubility determination. Next, CYP3A4
enzyme (25 pmol/mL) and BFC (20 µM) were dispensed into the
previous buffer/test compound solutions and reaction mixtures
were incubated with shaking for 15 min at 37◦C. Finally, reaction
product (7-HFC) formation was quantify using florescence
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measurements. All compounds were tested in triplicate in two
different days.
Assessment of CYP3A4 Time-Dependent Inhibition
Experiments were designed according to previous works with
minor modifications (Polasek and Miners, 2006). Briefly, pre-
incubation mixtures contained human recombinant CYP3A4
(25 pmol/mL), NADPH-regenerating system (1 mM NADP,
10 mM glucose 6-phosphate, 2 IU/mL glucose 6-phosphate
dehydrogenase, 5 mM MgCl2), test compound solutions (ERY,
RXT, CLT, AZT, and ketoconazole) at least five different
concentrations, and phosphate buffer (0.1 M, pH 7.4) in a total
volume of 500 µL. At 0, 5, 10, 15, 20, 25, or 30 min, BFC
(dissolved in AcN) was added so that the final concentration of
BFC in the incubations was 25 µM. Incubations were allowed to
proceed for a further 15 min at 37◦C. Reactions were terminated
with the addition of 75 µL of a STOP solution of AcN containing
0.5 M Tris base using a Multidrop liquid dispenser. Then
fluorescence for 7-HFC formation was determined using 430
nm as excitation and 535 nm as emission wave lengths by an
EnVision multilabel plate reader. Stock solutions of macrolides
were prepared in DMSO/AcN as previously described and added
to the pre-incubation mixtures so that the concentration ranges
were: ERY, RXT, and AZT, 0.133 to 32.5 µM; CLT, 0.06 to 16.2
µM; ketoconazole, 0.0021 to 0.512 µM. The DMSO content in
incubations was kept at 0.35% through all experiment. Control
samples were prepared in the absence of test compounds by the
addition of solvent alone.
Data analysis
The mean value of 7-HFC formation expressed as a percentage of
control was used to estimate the kinetic constants of inactivation
(Kinact and KI) according to related works (Silverman, 1995).
Briefly, the observed inactivation rate constant at each macrolide
concentration was calculated from the initial slopes of the
remaining enzyme activity, plotted semi-logarithmically against
the pre-incubation time. Non-linear regression analysis of the
negative slopes against inhibitor concentration enables Kinact
and KI to be calculated. Verapamil (tested at concentrations
ranging from 0.279 to 68 µM) was used as positive control.
All compounds were tested in triplicate in two different days
for every methodology studied. All compounds were tested in a
single experiment.
Simultaneous Determination of In vitro Metabolic
Profiling and Metabolic Stability
Test compounds (ERY, RXT, CLT, and AZT) were incubated in
HLM at an initial substrate concentration of 1 µM in a 96-
well format. Standard high-throughput incubation conditions
were used with time points of 0, 15, 30, 45, 60, and 90 min.
Protein concentration was 1 mg/mL and NADPH was present
at 4 mM. Reaction was quenched using an equal volume of
AcN and then diluted 1:1 with water prior to analysis by liquid
chromatography coupled to high resolution mass spectrometry
(LC-HRMS): Chromatography. The incubations were analyzed
using an Agilent Series 1290 LC system (Agilent Technologies,
Santa Clara, CA, USA). All analyses were performed using
a Supelco Discovery HS C18 (2.1 × 50 mm) 3 µm column
that was held at 30◦C. Solvent A contained water with 0.1%
formic acid and solvent B contained AcN with 0.1% formic
acid, and the flow rate was set at 400 µL/min.. The gradient
elution was performed as follows: 0–0.5 min 0% eluent B; 0.5–
7 min 100% eluent B; 7–9 min 100% eluent B; 9–9.2 min 0%
eluent B; and 9.2–10.5 min 0% eluent B. High resolution mass
spectrometry: AB SCIEX TripleTOF 5600 quadrupole-time-of-
flight mass spectrometer (Q-TOF-MS) in positive ESI mode
(AB SCIEX, Concord, ON, Canada) was used with a generic
method for data acquisition on all compounds and samples. The
method consisted of a time of flight mass survey scan (TOF
MS), followed by two information-dependent acquisitions (IDA)
TOF MS/MS scans. The mass range was m/z 100–1,000 for both
MS and MS/MS. An accumulation time of 100 ms was used for
each scan. Mass defect triggered IDA was used for the MS/MS
scans (collision energy of 35 eV with a spread of ±10 eV).
External mass calibration was performed automatically using a
calibrant delivery system. Data processing was performed using
MultiQuant Software and MetabolitePilot Software (AB SCIEX,
Concord, ON, Canada) to process the TOFMS data and generate
all quantitative information. An extracted ion current (XIC)
window of±10 mDa was used for all compounds.
Data Analysis
Peak areas were used to plot the Ln % remaining relative to t = 0.
The slope of the natural log of the percent remaining vs. time was
calculated to determine the first-order rate constant (k) and the
half-life (T1/2) of the test compounds according to Equation (2):
Half life (T1/2) = 0.693/k (min) (2)
Tentative metabolite identification was performed using
MetabolitePilot Software (AB SCIEX, Concord, ON, Canada).for
predicted and unpredicted metabolites, including fragment ion
interpretation from precursor high resolution MS/MS spectra
and potential cleavage metabolites. As a result a confirmation
score (from 0 to 100) is provided to rank metabolite peak
identification. In addition, formation rates of the metabolites
were correlated to different incubation times to investigate
metabolite stability. All compounds were tested in triplicate in
two different days.
Statistical Tests
Data replicates are presented as mean values ± STDEV. The
coefficient of variation (relative STDEV) of each set of replicate
data was calculated. A set of replicate date was considered
acceptable if the confident of variation was ≤20.
Production of RXT Main Hepatic
Metabolites
In order to provide a large enough amount of RXT main hepatic
metabolites, large-scale human microsomal incubations were
performed. Incubations were carried out in glass tubes containing
HLM (2mg of protein/mL), 5 mM MgCl2, 2 mM NADPH, 500
µMRXT, and 50mMphosphate buffer (pH 7.4) in a total volume
of 50 mL. After incubation in a 37◦C water bath shaker for 240
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min, the reactions were terminated by adding 50 mL of ice-cold
AcN. The mixture was vortexed for 3 min and centrifuged at
3,750 rpm for 15 min. The supernatant was collected and dried
under nitrogen gas flow. The residue was reconstituted with 100
mL of water. This concentrate was applied to a pre-conditioned
Waters Oasis HLB solid phase extraction (SPE) 96-well plates
(30 mg). The pre-conditioning step included washing with 1 mL
each of neat methanol and 20% aqueous methanol. The loaded
cartridge was washed with water, after which the metabolites
were eluted using 1 mL of methanol. After evaporation of SPE
elution and further reconstitution in 50 mL of water, liquid—
liquid extraction (LLE) was also applied as an isolation step. The
RXT metabolites extract was contacted with an organic solvent
[(methyl—ethyl ketone), 1:1] and shaken vigorously for 10 min.
Both, SPE and L/L procedures were optimized for achieving
maximum recuperation of main RXT metabolites which had
been previously described (Zhong et al., 2000). Centrifugation of
the liquid mixture at 805 g for 15 min separated the organic layer
from the aqueous layer. Samples from both layers were analyzed
for metabolite content by LC-HRMS. The aqueous layer was
dried under N2 current and further reconstituted in 5% aqueous
methanol for subsequent preparative HPLC (high performance
liquid chromatography) isolations which were performed using
an Atlantis T3 column, 10 × 250 mm, 5-µm particle size. For
isolation of metabolites, the mobile phase consisted of a linear
gradient from 5 to 95% of mobile phase B (AcN containing
0.1% formic acid) in 25 min. The flow rate was 2.3 mL/min
and UV absorbance was monitored at 290 nm. Fractions were
automatically collected every 0.25 min and further analyzed by
LC-HRMS. Each fraction was further analyzed by LC-HRMS
using a fast gradient in 3.5 min in order to assess the metabolite
purity and fraction enrichment. At this point it is important to
comment that in parallel, we carried out blank (not containing
RXT) large scale incubations that were equally subjected to
SPE, LLE and semi-preparative HPLC fractionation in order
to be used as false positive controls in the biological activity
assessment.
RESULTS
Effect of Dual Inhibitors on NO Oxide
Production and Correlated Measurements
of Solubility and CYP3A4 Inhibition
The results from the LPS stimulated RAW 264.7 macrophages
in vitro model showed that the 3 members of the imidazole
derivate family displayed moderate to weak inhibition potential
in NO production (IC50 = 7.20, >10 µM and 7.35 µM,
respectively, Table 1), in good agreement with previous works
using cultured cell line models (Bogle and Vallance, 1996).
However and based on their demonstrated ability to interact with
the heme moiety, we had expected a more intense potential to in
vitro inhibit NOS. Our experiments for the parallel determination
of CYP3A4 inhibition using isolated enzymes and aqueous
solubility confirmed the strong potential of these compounds to
inhibit the enzymatic activity (IC50 = 0.14–0.0045 µM, Table 1)
and their limited solubility (<10 µM, Table 1).
Our results for macrolides in LPS stimulated RAW 264.7
cells in contrast with those from primary cultures, showed IC50
values higher that the highest noncytotoxic dose (Table 1). Only
AZT and CLT had the ability to weakly inhibit the production
of NO at the highest noncytotoxic dose (53.82% of control
at 250 µM and 85.2% at 62.5 µM, respectively, as shown in
Figure 1). In order to check the extent of these interactions,
we tested the CYP3A4 inhibitory potency and the solubility
range of these macrolide members using NIVA (Table 1). As a
result, the CYP3A4 activity was inhibited but to a lesser extent
than with imidazole derivatives. Specifically ERY, ROX and CLT
displayed, among them, very similar IC50 values, in the range of
moderate inhibitors (from 1 to 10 µM) whereas AZT behaved as
a weak inhibitor (IC50 > 10 µM, Table 1). In terms of solubility,
macrolide compounds presented solubility limit values >86 µM
(Table 1).
In vitro Kinetics of CYP3A4 Inhibition by
Macrolides
In order to establish the in vitro macrolides kinetic constants of
CYP3A inhibition, ERY, CLT, RXT, and AZT were estimated by
varying the time of pre-incubation and the concentration. The
two major kinetic parameters that characterize time-dependent
inhibition interactions (TDIs) are the maximal inactivation rate
constant (Kinact) and the inhibitor concentration leading to 50%
of enzyme inactivation (KI), see Figure 2. The Kinact/KI ratio
is commonly taken as an indicator of the in vitro potency of a
mechanism-based inhibitor. The derived kinetic constants from
the inactivation experiments are presented in Table 1. Values of
Kinact and KI were in the range of 0.0399–0.0945 min−1 and of
0.146–7.349 µM, respectively, indicating that all 4 macrolides
inhibited in a time dependent manner the BFC conversion into
7-HFC in CYP3A4 human recombinant microsomes with an
inactivation potency (Kinact/KI ratio) in the following order: ERY
> RXT > CLT > AZT.
Macrolide In vitro Metabolic Stability
Following incubation in HLM, all four macrolides displayed
different half-life (T1/2) values in the range from 21 to >60
min. This value increased in the order ERY < RXT < CLT
< AZT (Table 1 and Figure 1). These results indicate that the
biotransformation rate of ERY and, consequently, the metabolite
formation is about double that of RXT and CLT while non-
detectable biotransformation was observed for AZT at the
referred incubation times.
RXT Metabolite Profile in HLM Incubations
The characterization of the in vitro metabolism of RXT was
achieved from the LC-HRMS data obtained in the metabolic
stability incubations. As a result, in addition to unchanged RXT,
a total of 5 stable potential metabolites were found (Table 2
and Figure 3A). Among them, besides the metabolites of RXT
identified by other investigators (Zhong et al., 2000) (ERY oxime
at m/z 749, demethylated ERY oxime at m/z 735 and N-mono-
demethylated RXT atm/z 823), we identified another 2 additional
stable biotransformation products (hydroxylated RXT at m/z
853 and demethylated and hydroxylated RXT at m/z 839). The
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TABLE 1 | Summary of the results obtained in the different in vitro models for the selected compounds.
Compound ID CYP3A4 RI CYP3A4 TDI Met. stability NO production Solubility Range
IC50 (µM) Kinac/KI (min
−1/µM) T1/2 (min) IC50 (µM)
Lower bound Upper bound
Miconazole 0.14 N.A. N.A. 7.35 8.62 34.48
Clotrimazole 4.51E-3 N.A. N.A. 7.21 2.59 10.35
Ketoconazole 3.32E-2 N.A. N.A. >10 2.59 10.35
Erythromycin 3.21 9.45E-2/0.15 (6.39E-1) 21.66 >250 >86 >86
Roxythromycin 6.41 4.29E-2/0.29 (1.47E-2) 38.08 >250 >86 >86
Claritromycin 4.03 3.99E-2/2.68 (1.49E-2) 50.59 >62.52 >86 >86
Azithromycin 16.1 8.23E-2/7.35 (1.11E-2) >60 >250 >86 >86
Ciclosporin A N.A. N.A. N.A. 1.16 N.A. N.A.
Dexamethasone N.A. N.A. N.A. 7.21E-3 N.A. N.A.
Verapamil N.A. 0.12/0.79 N.A. N.A. N.A. N.A.
RI, Reversible inhibition; TDI, Time dependent inhibition; Kinact, Rate of enzyme inactivation for time dependent inhibitors; KI, Inhibition constant for time dependent inhibitors; T1/2,
Half-life; NO, Nitric oxide.
molecular structure elucidation of the potential metabolites was
carried out by fragment interpretation of CID spectral data with
the assistance of chromatographic behaviors and basic rules of
drug metabolism. This is discussed in the following sections. The
relative content of each metabolite was estimated with reference
to RXT on the basis of peak area of their [M+H]+ ion. According
to this criteria, metaboliteM1 (ERY oxime at m/z 749) is themain
biotransformation product (20%) of RXT in HLM incubations.
The relative contents for the rest of metabolites (M2–M5)
ranged from 7 to 2% (Table 2) of RXT peak area as shown
in Figure 3B. The RXT metabolite profiling was monitored at
different incubation times, obtaining the same main metabolites
with very similar formation rates to those obtained in small scale
incubations (Figure 3C).
Isolation and Structure Elucidation of
Roxithromycin Metabolites
After SPE and LLE of RXT large scale incubations for isolation
of its main metabolites, semi-preparative HPLC chromatography
was used to obtained fractions containing RXT metabolites.
After several steps of isolation and purification guided by
the extracted ion chromatogram (XIC) of previously observed
metabolites, we achieved 1mg of highly enriched fraction (at
elution time of 12.5 min) in 2mainmetabolic products (M1&M5,
Figure 4A). As previously described, purity was assessed by
comparison of the detector response to the metabolites in the
incubation matrix with the response to a blank incubation matrix
at the same elution time (Figures 4B,C) (Espina et al., 2009;
Walker et al., 2011). The assessment by total ion chromatogram
(TIC) delivered a purity of 93% for the RXT metabolites
contained in that fraction, which is in line with the general
purity target for library compounds for activity screening
(Kassel, 2007). The identification of these metabolites was
achieved by comparative fragment ion interpretation with the
commercial reference substance of parent drug (RXT, chemically
designated as (E)-ERY-9-[O-[(2-methoxyethoxy)methyl]oxime])
and previously results from other investigators using LC-MS and
nuclear magnetic resonance (NMR) (Zhong et al., 2000). Briefly,
full scan high resolutionmass spectra of RXT reference substance
provided 2 chromatographic peaks with a 5-fold intensity ratio,
at identical m/z 837 but different retention times (2.41 and
2.54 min, see Figure 4D). Both chromatographic peaks displayed
the same MS/MS fragment ions at m/z 679, 558, 540, and 158
(Figure 5A), suggesting they were stereoisomers with tertiary
amino groups in their structure. They were thus identified
as RXT and its Z-stereoisomer. For metabolite M1, we also
observed 2 chromatographic peaks at retention times of 1.65 and
1.76 min, displaying a 7-fold intensity ratio (Figure 4B).They
showed identical protonated molecular ions [M+H]+ at m/z
749 as well as identical MS/MS fragment ions, indicating they
were also stereoisomers. Their protonated molecular ions (m/z
749) were 88 Da lower (characteristic loss of the alkylether
side chain) than that of the parent drug (m/z 837), indicating
they were O-dealkylated metabolites. The MS/MS spectra of
both peaks (parent ion at m/z 749) gave fragment ions at m/z
591, 434, and 158 Da (Figure 5B). The ion at m/z 591was 158
Da lower (loss of cladinose) than that of the precursor ion
(m/z 749), whereas the ion at m/z 434 was subsequently 157
Da lower (loss of desosamine) than the former ion. Based on
these data, they were identified as (Z)- and (E)-ERY-oxime,
respectively. For metabolite M5 the above described (Z) and
(E) isomers distribution was also observed at 1.65 and 1.76
min (Figure 4B). Their protonated molecular ions (m/z 735)
were 102 Da lower than that of the parent drug, indicating a
cleavage of the alkylether side chain (88 Da), followed by the
loss of a methyl group. The MS/MS spectra of m/z 735 gave
ions at m/z 577, 434, and 144 (Figure 5C). The diagnostic ions
at m/z 434 indicated that the 14-member lactone ring nucleus
was unaltered. The loss of the cladinose moiety produced the
peak at m/z 577, suggesting that the demethylation was carried
out on the desosamine that was confirmed by the peak at
m/z 144 (Figure 5C). Based on these data these peaks were
identified as N-monodemethylated derivatives of (Z)- and (E)-
ERY-oxime, respectively. The stereochemical aspects of RXT
and its metabolites have been extensively described in previous
works using LC-MS in combination with NMR and our results
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FIGURE 1 | (Left) Dose-dependent effects of macrolide antibiotics on the release of NO from LPS-stimulated murine macrophages. The cells were incubated for 24 h
with various concentrations of ERY (A), RXT (B), CLT (C), and AZT (D). Max doses (250 µM for ERY, RXT and AZT and 62.5 µM for CLT) were adjusted to achieve a
cell viability ≥ 80%. Values on the vertical axe represent the percentage of control of NO formation in the culture medium after addition of LPS. (Right) Human in vitro
liver microsome stabilities (n = 3 per time point) for ERY (E), RXT (F), CLT (G), and AZT (H). Data are means ± STDEV; n = 6 for each concentration and time point.
are consistent with them (Zhong et al., 2000). Therefore, 2
RXT major metabolites (M1–M5) and their corresponding (Z)-
isomers were isolated from the rest of the components of
microsomal incubations in a semi-preparative HPLC fraction
which yielded a dry weight of 1 mg. Since our main objective
was to clarify the implication of RXT metabolites in inactivation
of NO production and not activity ascription, we considered
that isolation of single metabolites was not critical, being much
more important the separation from parent drug (RXT) and
main matrix components. Regarding the relative composition we
could conclude from XICs that metabolite M1and M5 represents
78% [68 and 10% for (E) and (Z)-isomers, respectively] and 15%
[14 and 1% for (E) and (Z)-isomers, respectively] of the total
dry amount, respectively. It is very interesting to notice that the
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FIGURE 2 | The macrolides CYP3A4 time dependent inhibition: Compounds were evaluated by pre-incubating a range of 6 test compound
concentrations to achieve a scale from no inactivation to maximal inactivation, for 6 differing pre-incubation times with human rCYP3A4 and NADPH.
Following the pre-incubation, an aliquot of the pre-incubation mixture is diluted with buffer containing a specific cytochrome P450 probe substrate (7-HFC) for a
specific incubation time (data are singletons for each time and concentration point). (A) Inactivation plot (natural logarithm of the % remaining activity vs.
pre-incubation time) for CLT. The least-squares regression analysis enables to determine the negative slope of the logarithm of the % remaining activity vs.
pre-incubation time. (B) The non-linear regression analysis of the negative slopes against inhibitor concentration enables Kinact and KI to be calculated. The Kinact is
the maximal rate of enzyme inactivation at a saturating concentration of inhibitor and KI is the concentration of inhibitor which gives half the maximal rate of
inactivation. Similar time- and concentration-dependent inhibition profiles were observed ERY, RXT, and AZT (data not shown).
TABLE 2 | Summary of key LC/HRMS data of in vitro metabolites after RXT incubation with HLM.
Peak ID Description Formula m/z Mass error (ppm) R.T. (min) Peak area Area (%) Score (%)
RXT (Parent) C41H76N2O15 837.5331 1.5 4.12 7.78E+05 65 93.9
M1 ERY oxime C37H68N2O13 749.4805 1.5 3.64 2.37E+05 20 93.7
M2 Demethylatied + Hydroxylated RXT C40H74N2O16 839.5118 0.8 3.52 8.74E+04 7 86.1
M3 N-mono-demethylated RXT C40H74N2O15 823.5169 0.9 3.68 3.57E+04 3 95.5
M4 Mono hydroxylated RXT C41H76N2O16 853.527 0.3 3.74 2.46E+04 2 79.3
M5 Demethylated ERY oxime C36H66N2O13 735.4638 0.1 3.56 2.82E+04 2 81.5
(E)-isomer of RXT was reported to be the more potent of the two
geometric forms in antibacterial tests and consequently, RXT in
clinical use exclusively contains this isomer (Zhong et al., 2000).
Hence, we can assume that the observed therapeutically effects
are due to the (E) isomers of either RXT or its metabolites.
Biological Evaluation of Isolated RXT
Metabolites
Considering previously reported RXT IC50 value (5 µg/mL)
in NO production using primary cultures of alveolar rat
macrophages, we dissolved the dry amount (1mg) of RXT
metabolites (M1, M5 and the corresponding geometric isomers)
in 0.133 mL of pure DMSO (Tamaoki et al., 1999; Kohri et al.,
2000). After ½ serial dilution in DMSO, the metabolite mixture
was 1/5 diluted in water in order to minimize the DMSO content,
and it was finally tested (max dose 35 µg/mL) in triplicate
using the LPS stimulated RAW 274.6 macrophage model to
evaluate its ability to inhibit NO production. The mixture of RXT
metabolites had the ability to inhibit NO production to 50% at a
concentration of 31.6 µg/mL (Figure 6) while no inactivation at
all of NO production was observed for RXT from 0.488 to 250
µM (Figure 1B).
Considering relative composition of the RXT metabolite
mixture and the previously discussed isomer activity ascription, it
is possible to infer an IC50 value of 23.07 and 4.74 µg/mL for M1
and M5, respectively, for inactivation of NO production. These
values are in line with the previously reported RXT IC50 value (5
µg/mL) in NO production using primary cultures of alveolar rat
macrophages.
DISCUSSION
In order to characterize the involvement of the CYP450
enzymatic system in immunomodulatory properties of the
previously described molecules (imidazole derivatives and
macrolides), we selected representative members of the 2 families
of compounds (ketoconazole, miconazole and clotrimazole
from the imidazole derivate family, and ERY, RXT, CLT
and AZT from macrolides family) for the assessment of NO
production in the LPS stimulated RAW 264.7 macrophage in
vitro model. Therefore, and taking into consideration that a loss
of biotransformation activity has been observed in cultured cells
(RAW 264.7) caused by a decrease in CYP450 transcription in
comparison with primary cell cultures (alveolar macrophages)
or in vivo experimental systems, a differential response in NO
production should be expected for dual inhibitors depending
on the considered experimental model (Rodríguez-Antona et al.,
2002; Zarogoulidis et al., 2012). Thus, a compound being
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FIGURE 3 | Time course of RXT incubations with HLM. (A) Representative combined extracted ion chromatogram (XIC) of RXT and its metabolites at 30 min
incubation time. The main peak at 4.12 min was identified as RXT by direct comparison with the authentic standard. The rest of peaks correspond to RXT metabolites,
which were not observed in the control samples. (B) Time course of RXT at small scale incubation. (C) Time course of RXT at large scale incubation (data are
singletons for each incubation time).
intensively metabolized by CYP450 should display a higher
inhibition potential over NO production in this in vitro model
(LPS stimulated RAW264.7) with reduced CYP450 functionality.
On the contrary, a compound producing active metabolites via
CYP450 should show a reduced potential to inhibit NO in
comparison with other in vitro models with regular CYP450
functionality. Our results for imidazole derivatives in NO
production when compared with the in vivo results reported
for related azole compounds (even at higher doses) showing
no inhibition of NOS activity, support, this way, our working
hypothesis in which the diminished CYP450 activity in RAW
264.7 cells may have some influence on NO production (Dercho,
2015). In this case, the absence of compound depletion may
contribute to the moderate IC50 values obtained in comparison
with the complete lack of inhibition NO production observed
using an in vivo experimental system. The CYP3A4 inhibition
data showed that imidazole derivatives exerted their inhibition
ability on CYP3A4 in the soluble range, suggesting that their
limited solubility (upper solubility limit from 10.35 to 34 µM)
could be related with the moderate ability to in vitro inhibit
NOS and even with the lack of in vivo response. Therefore, it is
reasonable to expect that the actual cytoplasmatic concentration
of imidazole derivatives in RAW 264.7 cells might be much lower
than anticipated and hence, might show artificially low inhibition
on NO production. In fact, the IC50 values (0.14µM) obtained by
other investigators for ketoconazole on CYP3A4 activity using
cryopreserved hepatocytes were 4-fold higher than those got in
our experiment with recombinant CYP3A4 enzymes (0.033 µM)
(Moeller et al., 2012).
In the case of macrolides, other investigators have
demonstrated that these compounds (ERY, RXT and CLT)
could inhibit the production of NO in either primary cultures
of stimulated rat pulmonary alveolar macrophages or stimulated
animal models model by down-regulation of NOS gene
expression (Hukkanen, 2000; Zhong et al., 2000; Kanoh and
Rubin, 2010). However the therapeutic mode of action and the
biotransformation of macrolides are not well understood and
many questions remain unanswered, such as the role of NOS
inhibition or the implication of their main metabolites in the
therapeutic response. Our in vitro results showing a lack of
potential activity to inhibit NO production in comparison with
other experimental systems with drug metabolic competence
also supported our previously exposed working hypothesis and
it points toward the critical role of macrolide biotransformation
via CYP450 in the inactivation of NO production. Our data from
CYP3A4 reversible inhibition confirm the differential ability of
these compounds to inhibit CYP3A4 activity in a concentration
dependent manner which interestingly correlates reversely with
their potential to inhibit NO production in LPS stimulated
RAW 264.7 cells (Figure 1, left and Table 1). The results from
our macrolide KS experiments enabled to suppress the effect of
solubility issues in the observed results.
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FIGURE 4 | LC-HRMS chromatograms of RXT metabolite isolation using fast gradient separation. (A) Extracted ion chromatogram (XIC) of semi-preparative
fraction (at elution time 12.5) for expected RXT metabolites showed 3 main peaks: 2 peaks at m/z 749.4805 (in black color line) at 1.65 and 1.76 min corresponding
to (Z)-ERY-oxime and (E)-ERY-oxime (M1), respectively and 1 peak at m/z 735.4638 (in light gray color line) and 1.76 min, corresponding to metabolite M5. Although
very weakly the corresponding (Z) isomer was also observed at 1.65 min. (B) TIC (50-1000 Da) of semi-preparative fraction (at elution time 12.5. (C) TIC (50-1000 Da)
of semi-preparative fraction from blank incubation at 12.5 min elution time. (D) XIC of RXT reference substance showed 2 peak at m/z 837.5331 corresponding to
RXT (2.54 min) and its Z-stereoisomer (2.41 min), which were not observed in the metabolite enriched fraction, ensuring the absence of parental drug.
Macrolide antibiotics have been previously described as
mechanism-based inactivators of CYP3A enzymes that exhibit
varying degrees of inhibitory potency. Mechanism-based
inhibition often involves the metabolism of an inhibitor
by CYP3A4 to a reactive metabolite, which inactivates the
catalyzing enzyme in a concentration and time-dependent
manner. The interaction between the inactivating species and
the enzyme can either be covalent or non-covalent, involving
binding to protein or heme moiety, respectively (Polasek and
Miners, 2006). From our results in CYP3A4 time dependent
inhibition experiments, we can assert that for these macrolide
antibiotics, CYP3A4 is responsible for the production of active
metabolites which might be central to inhibit NO production.
Hence, important information can be drawn:
First, although ERY, RXT, and CLT got very similar IC50
values from CYP3A4 reversible inhibition, we can observe a
clear shift in Kinact/KI ratio from ERY and RXT (0.64 and 0.14
min−1/µM, respectively) to CLT and AZT (0.014 and 0.010
min−1/µM, respectively). These results indicate that product
metabolites from ERY and RXT are much more potent inhibitors
than those produced from CLT and AZT which is on line with
the differential CYP3A4inhibition potency observed among the
macrolides in the clinic (Polasek and Miners, 2006).
Second, the inability of RAW 264.7 cells to produce these
active metabolites might partially explain the lack NO inhibition
observed for macrolides in this cell line.
The in vitro metabolic stability, expressed as intrinsic T1/2
of selected macrolide antibiotics, was investigated in HLM
incubations. Pointing in the same direction as TDI results,
these data also showed that compounds undergoing more
intense biotransformation (ERY and RXT) did not affect NO
production in RAW 267.4 cell lines (Figures 1A,B,E,F) while
those displaying higher microsomal stability (CLT and AZT)
exert a certain degree of inactivation in NO production
(Figures 1C,D,G,H). This fact suggests that the reduced
expression CYP450 isoform and the subsequent lack of reactive
metabolites might be the cause of the inability of ERY and
RXT to inhibit NO production in RAW 267.4 cell lines.
Although higher quantity and distribution of metabolites is
expected for ERY based on our stability results, the more
abundant previous information related to in vivo and in
vitro metabolism as well as the increasing interest aroused by
RXT’s anti-inflammatory and immunomodulatory properties in
clinical practice, led us to select this macrolide to explore its
in vitro metabolic profile in detail (Yamazaki and Shimada,
1998; Tamaoki et al., 1999). For RXT, as stated in the result
section, main biotransformation took place in N-oxime ether
side chain attached to the lactone ring, rendering an oxime
functional group. This metabolism feature leads to a higher
exposition of imine moiety (carbon–nitrogen double bond)
which is also observed in imidazole derivatives and suggests that
this biotransformation and the corresponding metabolites may
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FIGURE 5 | Proposed biotransformation route from RXT to metabolites ERY oxime (M1) and Demetylated ERY oxyme in HLM incubations. The loss of 88
Da from RXT at [M+H]+ = 837.5331 to M1 at [M+H]+ = 749.4805 Da is fully compatible with the loss of the alkylether side chain. Fragment ion analysis of MS/MS
spectrum from RXT (A) and M1 (B) revealed an analog loss of 88 Da from m/z = 679 Da in RXT to m/z = 591 Da in M1, confirming the site of alkylether chain at the
lactone ring. The ion at m/z 591was 158 Da lower (loss of cladinose) than the precursor ion (m/z 749), whereas the ion at m/z 434 was subsequently 157 Da lower
(loss of desosamine) than the former ion. Based on these data, M1 was identified as ERY-oxime. The difference of 14 Da between M1 at [M+H]+ = 749.4805 Da and
M5 at [M+H]+ = 735.4638 Da indicated the loss of a methyl group in the biotransformation. The MS/MS spectra of m/z 735 Da (C) gave fragment ions at m/z 577,
434, and 144 Da. The ions at m/z 434 Da indicated the lactone ring was unaltered. The loss of the cladinose moiety produced the peak at m/z 577 Da, suggesting
that the demethylation took place at the desosamine that was confirmed by the peak at m/z 144 Da. Based on these data M5 identified as demethylated ERY oxime.
have a key role in differential clinical effects observed for RXT
(Zarogoulidis et al., 2012).
Authentic standards of drug metabolites are valuable reagents
for carrying out experiments aimed toward understanding the
disposition, efficacy, and safety of drugs. However, obtaining
metabolite standards by conventional organic synthesis can
frequently be challenging, expensive, and they can take weeks
to months to prepare. As an alternative approach, the biological
generation and isolation of metabolites from source material
obtained from in vivo or in vitro studies has been proved to
useful for the production of isolates in the nanomole range.
Metabolites obtained using these approaches can be used to
test target activity, they can be used as authentic standards for
quantitative bioanalysis of in vivo and in vitro samples by HPLC-
MS, and they can also be used in other in vitro drug metabolism
experiment. In order to isolate main microsomal metabolites of
RXT with the objective of assessing their involvement of NO
modulation, we carried out a large scale incubation as described
in methods and materials section. Therefore, we can assert from
our results that the metabolites of RXT (M1&M5) demonstrated
significant activity as inhibitors of NO production, affording
better activity than the parent drug in LPS stimulated RAW 274.6
macrophage cell lines.
Although our results showed that quite high concentrations
of RXT metabolites are required to inhibit NOS activity,
the relevance of this in vitro observations should be taken
into consideration since there are clear and compelling data
demonstrating their nonantimicrobial properties of macrolide,
such as their ability to decrease the hypersecretion of key
regulators of the inflammatory response in cell culture, in animal
models of disease, and in persons with chronic inflammatory
pulmonary diseases (Kanoh and Rubin, 2010). It has been
proven that macrolides can decrease mucus hypersecretion
both in vitro (Okamoto et al., 1999) and in vivo (Tamaoki
et al., 1995; Rubin et al., 1997). In particular, physiological
concentrations of ERY and CLT inhibit IL-8 mRNA and protein
in bronchial epithelial cells from healthy subjects and those with
chronic inflammatory airway diseases (Takizawa et al., 1997).
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FIGURE 6 | Dose-dependent effects of RXT metabolites (M1 and M5)
on the release of NO from RAW 264.7 mouse macrophages stimulated
with LPS. Data are means ± STDEV from experiments in triplicate (n = 3) for
each concentration point.
ERY at a concentration of 10 µg/ml inhibited IL-6, IL-8, and
soluble intercellular adhesion molecule 1 secretion from human
bronchial epithelial cells stimulated by endotoxin (Khair et al.,
1995). ERY decreased production of tumor necrosis factor Alpha
and IL-6 in human whole blood stimulated with heat-killed
Streptococcus pneumoniae (Schultz et al., 1998). Similar effects
have been observed using RXT, which suppressed the production
of IL-6, IL-8 in the human epithelial cell line Bet-1A stimulated
with IL-1α (Kawasaki et al., 1998). These immunomodulatory
activities appear to be polymodal, so macrolides accumulate
within cells, suggesting that they may associate with receptors
or carriers responsible for the regulation of cell cycle and
immunity (Kanoh and Rubin, 2010). The characteristics of the
clinical nonantimicrobial properties ofmacrolide therapy include
effective doses that are much lower than the minimal inhibitory
concentration (i.e., low-dose macrolide therapy) (Nagai et al.,
1991; Fujii et al., 1995; Kudoh et al., 1998; Shitrit et al., 2005).
As general mechanism of in vivo inhibition, we propose two
compatible approaches. First, as previously described alveolar
macrophages represent a clear evidence for co-expression of these
enzymes (CYP450s and NOS) and this can be consider as a
common fact to other cell types in primary sites of exposure for
chemical toxicants such as hepatic macrophages which present
an expression pattern of CYP450 specifically adapted for their
major role in the protection of the organism (Rubin et al.,
1997; Okamoto et al., 1999; Hukkanen et al., 2002). Therefore
it makes sense to expect that compound biotransformation and
NOS inhibition might take place in the same cell. Second and
in parallel, hepatic metabolites might be cleared to plasma and
distributed systemically to immune system cells and epithelial
tissues in which might inhibit NOS activity.
CONCLUSIONS
This study represents an initial comprehensive characterization
of CYP450 involvement in immunomodulatory response in
the macrophage cell lines. Even though the assessment of
CYP450 protein levels, inter-species metabolic differences and
activity measurements will be necessary to further validate and
confirm our results, this study suggests that the metabolites
of RXT might be responsible for some of the observed
pharmacological activity of RXT, highlighting the role of
CYP450 activity in the development of the pharmacological
immunomodulation, especially for those compounds undergoing
time-dependent biotransformations through this enzymatic
system.
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